Pablo Lira

Vivienda en altura en zonas de renovación urbana: desafíos para mantener su vigencia

issn impreso 0250-7161 | issn digital 0717-6236 Este articulo se basa en la version diciembre 2010 de la Memoria Explicativa PRMS 100 (ver http://www.seremi13minvu.cl/ opensite_20110103164100.aspx). Como premisa a este articulo, el autor aclara que, en su opinion, el limite urbano constituye un instrumento de planificacion valido y necesario, que por su naturaleza puede y debe ser modificado cuantas veces sea necesario. vol 37 | n 111 | mayo 2011 | pp. 185-189 | tribuna | ©EURE

Leucemia de células velludas en el embarazo: Caso clínico

Hairy cell leukemia (HCL) is a rare chronic B cell lymphoproliferative disorder that affects mostly men. It usually presents with pancytopenia, splenomegaly and bone marrow infiltration, without lymphadenopathy. Diagnosis is based on the presence of mononuclear cells with cytoplasmic projections in a blood smear, the typical bone marrow infiltration pattern and the immunophenotypic profile. HCL occurs seldom in young women and even more exceptionally during pregnancy. We report a 31-year-old woman in whom a splenomegaly was detected during routine prenatal care. Pancytopenia with 25% of hairy cells was found in her blood count. The patient was subjected to an open splenectomy and had an uneventful pregnancy. After two years of follow up, she has a normal blood count and has not required chemotherapy.

Leucemia de células natural killer: Caso clínico

Natural killer leukemia is a rare and highly aggressive neoplasm,is more common in young male patients and has a very poor prognosis, with a median survivalof few weeks. We report a 17 years old male patient who developed, after an acute upperrespiratory disease, a rapidly multiorganic failure with pancytopenia. Bone marrow aspirationand trephine biopsy showed an acute lymphoblastic leukemia. The immunophenotype andimmunohistochemistry revealed a natural killer acute leukemia. The disease progressed rapidlyand the patient died shortly after the diagnosis (Rev Med Chile 2005; 133: 457-60).(

Experiencia de 22 años de trasplante autólogo de células hematopoyéticas en pacientes con mieloma múltiple o amiloidosis sistémica. 1992-2014

BACKGROUND Autologous hematopoietic cell transplantation (THA) in patients with multiple myeloma and amyloidosis is the standard of care to promote disease free survival and quality of life. AIM To report our experience with THA in patients with multiple myeloma. MATERIAL AND METHODS Retrospective review of the hematopoietic cell transplantation database of a hospital of a Medical School. Forty seven patients with multiple myeloma and six with amyloid light chain amyloidosis were identified. Clinical and demographic data were obtained from the records. RESULTS The overall five year survival of patients was 55%. Transplant-related or non-relapse mortality occurred in 7%. We found no differences in outcomes among patients younger or older than 50 years. CONCLUSIONS Our data supports that THA can be done in our country with similar results to those obtained in international transplantation centers. Chronological age should not be a limitation to offer this therapy to patients with multiple myeloma and amyloidosis.Background: Autologous hematopoietic cell transplantation (THA) in patients with multiple myeloma and amyloidosis is the standard of care to promote disease free survival and quality of life. Aim: To report our experience with THA in patients with multiple myeloma. Material and Methods: Retrospective review of the hematopoietic cell transplantation database of a hospital of a Medical School. Forty seven patients with multiple myeloma and six with amyloid light chain amyloidosis were identified. Clinical and demographic data were obtained from the records. Results: The overall five year survival of patients was 55%. Transplant-related or non-relapse mortality occurred in 7%. We found no differences in outcomes among patients younger or older than 50 years. Conclusions: Our data supports that THA can be done in our country with similar results to those obtained in international transplantation centers. Chronological age should not be a limitation to offer this therapy to patients with multiple myeloma and amyloidosis.

Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto

Treatment of intermediate and high grade non-Hodgkin lymphoma (NHL) includes chemotherapy with or without radiotherapy, depending on theclinical stage. The standard treatment for advanced NHL is 8 cycles of combined chemotherapy,cyclophosphamide, adriamicin, vincristine and prednisone (CHOP). Patients presenting with localizeddisease are treated with fewer chemotherapy cycles and involved field radiotherapy, with good results.